Cardiovascular events associated with ipratropium bromide in COPD.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Chest

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1378/chest.08-2367PMID 19363211
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A 4-year trial of tiotropium in chronic obstructive pulmonary disease.

  2008cited by this paper
• Cardiovascular morbidity and the use of inhaled bronchodilators

  2008cited by this paper
• Risk for Death Associated with Medications for Recently Diagnosed Chronic Obstructive Pulmonary Disease

  2008cited by this paper
• Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.

  2008cited by this paper
• Veterans’ Access to and Use of Medicare and Veterans Affairs Health Care

  2007cited by this paper
• Meta-analysis: Anticholinergics, but not β-agonists, reduce severe exacerbations and respiratory mortality in COPD

  2006cited by this paper
• Spirometry use in clinical practice following diagnosis of COPD.

  2006cited by this paper
• COPD exacerbations · 1: Epidemiology

  2006cited by this paper
• The role of anticholinergics in chronic obstructive pulmonary disease.

  2004cited by this paper
• Is there any association between inhaled ipratropium and mortality in patients with COPD and asthma?

  2003cited by this paper
• Inhaled corticosteroids in chronic obstructive pulmonary disease and risk of death and hospitalization: time-dependent analysis.

  2003cited by this paper
• Hospitalizations and mortality in the Lung Health Study.

  2002cited by this paper
• Risk factors for death from asthma, chronic obstructive pulmonary disease, and cardiovascular disease after a hospital admission for asthma

  1999cited by this paper
• Carvedilol and the Food and Drug Administration approval process: an introduction.

  1999cited by this paper
• Time-dependent covariates in the Cox proportional-hazards regression model.

  1999cited by this paper

• Evaluating Arrhythmia Risk in Patients with Chronic Obstructive Pulmonary Disease Treated with Aclidinium/Formoterol Fumarate and Other Inhaled Bronchodilators: A Post-Authorization Safety Study

  2026cites this paper
• A deep dive into atrial fibrillation in chronic obstructive pulmonary disease

  2026cites this paper
• Performance-Enhancing Effects of Inhaled Medications: Implications for Heart, Muscle Function, and Doping Detection in Athletes

  2025cites this paper
• Cardiovascular Events with the Use of Long-Acting Muscarinic Receptor Antagonists: An Analysis of the FAERS Database 2020–2023

  2024cites this paper
• Electrocardiographic alterations in chronic obstructive pulmonary disease.

  2024cites this paper
• Insights into Drug Cardiotoxicity from Biological and Chemical Data: The First Public Classifiers for FDA DICTrank

  2023cites this paper
• Risk Assessment of Acute Myocardial Infarction and Stroke Associated with Long-Acting Muscarinic Antagonists, Alone or in Combination, versus Long-Acting beta2-Agonists

  2022cites this paper
• Design of the reducing diagnostic error to improve patient safety (REDEfINE) in COPD and asthma study: A cluster randomized comparative effectiveness trial.

  2022cites this paper
• Statistical Analysis and Machine Learning Prediction of Disease Outcomes for COVID-19 and Pneumonia Patients

  2022cites this paper
• COPD_A_363997 1715..1733

  2022cites this paper
• COPD Management in Community Pharmacy Results in Improved Inhaler Use, Immunization Rate, COPD Action Plan Ownership, COPD Knowledge, and Reductions in Exacerbation Rates

  2021cites this paper
• Chronic obstructive pulmonary disease and atrial fibrillation

  2021cites this paper
• COPD_A_288792 519..533

  2021cites this paper
• Title: The use of Ipratropium and Tiotropium as novel agents to reduce inflammation in in vitro macrophage models. Author: Ifteqar

  2021cites this paper
• A Cohort Study to Evaluate the Risk of Hospitalisation for Congestive Heart Failure Associated with the Use of Aclidinium and Other Chronic Obstructive Pulmonary Disease Medications in the UK Clinical Practice Research Datalink

  2021cites this paper
• Switching to nebulised short acting bronchodilators does not increase the risk of arrhythmia in patients hospitalized with a COPD exacerbation.

  2021cites this paper
• The use of Ipratropium and Tiotropium as novel agents to reduce inflammation in in vitro macrophage models

  2021cites this paper
• COPD_A_242009 1015..1037

  2020cites this paper
• Acute Exacerbations of Chronic Lung Disease: Cardiac Considerations

  2020cites this paper
• Management of the COPD Patient with Comorbidities: An Experts Recommendation Document

  2020cites this paper
• Characterising the cardiovascular safety profile of inhaled muscarinic receptor antagonists

  2020cites this paper
• Asthma: Pathophysiology, Current Status, and Therapeutics

  2020cites this paper
• Management of cardiovascular comorbidities in chronic obstructive pulmonary disease patients

  2020cites this paper
• Cardiac Considerations in Chronic Lung Disease

  2020cites this paper
• Nebulized Ipratropium bromide protects against tracheal and bronchial secretion during bronchoscopy

  2019cites this paper
• Comparison of Beers criteria and EU(7) potentially inappropriate medications list for the potentially inappropriate medications in Indian elderly inpatients

  2019cites this paper
• [Chronic obstructive pulmonary disease and cardiovascular comorbidity].

  2019cites this paper
• GOLD assessment of COPD severity in the Clinical Practice Research Datalink (CPRD)

  2019cites this paper
• Predicting Acute Exacerbations in Chronic Obstructive Pulmonary Disease

  2018cites this paper
• Chronic obstructive pulmonary disease and atrial fibrillation: An unknown relationship.

  2017cites this paper
• Risk of Cardiovascular and Cerebrovascular Events in COPD Patients Treated With Long-Acting β2-Agonist Combined With a Long-Acting Muscarinic or Inhaled Corticosteroid

  2017cites this paper
• Chronic Obstructive Pulmonary Disease: Diagnosis and Management.

  2017cites this paper
• Cardiovascular safety of new inhaled medications for asthma and chronic obstructive pulmonary disease: a critical review from pharmacist perspective

  2016cites this paper
• Comprehensive therapeutic approach for patients with heart failure and comorbidity

  2016cites this paper
• Comprehensive therapeutic approach for patients with heart failure and comorbidity.

  2016cites this paper
• Chronic Obstructive Pulmonary Disease and Cardiac Diseases. An Urgent Need for Integrated Care.

  2016cites this paper
• Bronchodilating drugs for chronic obstructive pulmonary disease: current status and future trends.

  2015cites this paper
• Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.

  2015cites this paper
• Therapeutic Class Overview Inhaled Anticholinergics

  2015cites this paper
• Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease.

  2015cites this paper
• Factors predictive of airflow obstruction among veterans with presumed empirical diagnosis and treatment of COPD.

  2015cites this paper
• COPD and pulmonary function in heart failure: a matter of definition

  2015cites this paper
• Adverse reactions to anticholinergic agents used in the management of obstructive pulmonary disease

  2015cites this paper
• [Are there cardiovascular adverse effects of inhaled anticholinergics?].

  2015cites this paper
• Electrocardiographic abnormalities and cardiac arrhythmias in chronic obstructive pulmonary disease.

  2015cites this paper
• Medikamentöse Therapie von Herz- und Lungenerkrankungen

  2014cites this paper
• in Heart Failure: Drugs to Use and Avoid

  2014cites this paper
• The in vitro and in vivo profile of aclidinium bromide in comparison with glycopyrronium bromide.

  2014cites this paper
• Disease and drug-induced arrhythmias : the example of obstructive pulmonary disease

  2014cites this paper
• Risk of Arrhythmias Associated with Ipratropium Bromide in Children, Adolescents, and Young Adults with Asthma: A Nested Case‐Control Study

  2014cites this paper
• Inhaled anticholinergic use and all-cause mortality among elderly Medicare beneficiaries with chronic obstructive pulmonary disease

  2013influential citation
• Guidelines for diagnosis and management of chronic obstructive pulmonary disease: Joint ICS/NCCP (I) recommendations

  2013cites this paper
• Long-term safety and efficacy of twice-daily aclidinium bromide in patients with COPD.

  2013cites this paper
• Expertentreffen obstruktive Atemwegserkrankungen : Kardiovaskuläre Aspekte der COPD * Expert Meeting Chronic Obstructive Airway Disease – Cardiovascular Aspects of COPD

  2013cites this paper
• Optimizing safety of COPD treatments: role of the nurse practitioner

  2013cites this paper
• Inhaled muscarinic acetylcholine receptor antagonists for treatment of COPD.

  2013cites this paper
• Efficacy and safety of eco-friendly inhalers: focus on combination ipratropium bromide and albuterol in chronic obstructive pulmonary disease

  2013cites this paper
• A woman with breathlessness: a practical approach to diagnosis and management

  2013cites this paper
• Evaluating the safety of COPD medications: an evidence-based review.

  2013cites this paper
• Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease.

  2013cites this paper
• Expertentreffen obstruktive Atemwegserkrankungen: Kardiovaskuläre Aspekte der COPD

  2013cites this paper
• Safety and tolerability of inhalational anticholinergics in COPD

  2013cites this paper
• Treatment of stable chronic obstructive pulmonary disease: the GOLD guidelines.

  2013cites this paper
• Chronic Obstructive Pulmonary Disease in Older Patients

  2012cites this paper
• Elevated cardiovascular risk among adults with obstructive and restrictive airway functioning in the United States: a cross-sectional study of the National Health and Nutrition Examination Survey from 2007–2010

  2012cites this paper
• A new user cohort study comparing the safety of long-acting inhaled bronchodilators in COPD

  2012cites this paper
• Pharmacology and Therapeutics of Bronchodilators

  2012cites this paper
• An Evidence-Based Approach to COPD: Part 1

  2012cites this paper
• Risk of stroke associated with inhaled ipratropium bromide in chronic obstructive pulmonary disease: a population-based nested case-control study.

  2012cites this paper
• Drugs that act on the respiratory tract

  2012cites this paper
• Pharmacologic Treatment Strategies

  2012cites this paper
• Bronchodilators in heart failure patients with COPD: is it time for a clinical trial?

  2012cites this paper
• AN OVERVIEW ON SYMPTOMS CAUSES TEST TREATMENT FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE

  2012cites this paper
• Management of Stable COPD: Focus on

  2012cites this paper
• Risk of Arrhythmias Associated with Inhaled Anticholinergics in Young Individuals with Asthma

  2012cites this paper
• Cardiovascular Events Associated With Ipratropium Bromide in COPD

  2011cites this paper
• Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials

  2011cites this paper
• Comparison of Inhaled Long-Acting (cid:1) -Agonist and Anticholinergic Effectiveness in Older Patients With Chronic Obstructive Pulmonary Disease A Cohort Study

  2011cites this paper
• Comparison of Inhaled Long-Acting β-Agonist and Anticholinergic Effectiveness in Older Patients With Chronic Obstructive Pulmonary Disease

  2011cites this paper
• 25 Acetylcholine protects against ipratropium induced myocardial injury

  2011cites this paper
• Comparison of Inhaled Long-Acting (cid:1) -Agonist and Anticholinergic Effectiveness in Older Patients With Chronic Obstructive Pulmonary Disease A Cohort Study

  2011cites this paper
• The Effect of Administrative Cessation of the Use of Ipratropium Bromide in the Treatment of Acute Asthma Attacks in the Emergency Department

  2011cites this paper
• Mortalityassociatedwithtiotropiummistinhalerinpatients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials

  2011cites this paper
• Subchronic toxicity and toxicokinetics of long-term intranasal administration of bencycloquidium bromide: a 91-day study in dogs.

  2011cites this paper
• Outpatient management of severe COPD.

  2010cites this paper
• The cardiovascular risk of tiotropium: is it real?

  2010cites this paper
• Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme

  2010cites this paper
• Insufficient evidence for chest CT scan in TB outbreak investigation.

  2010cites this paper
• Inhaled albuterol/salbutamol and ipratropium bromide and their combination in the treatment of chronic obstructive pulmonary disease

  2010cites this paper
• Insuffi cient Evidence for Chest CT Scan in TB Outbreak

  2010cites this paper
• Safety of ipratropium bromide.

  2010cites this paper
• Serodiagnosis of pulmonary disease due to Mycobacterium avium complex proven by bronchial wash culture.

  2010cites this paper
• An overview of the benefits and drawbacks of inhaled corticosteroids in chronic obstructive pulmonary disease

  2010cites this paper
• Safety of Ipratropium Bromide: Response

  2010cites this paper
• Current awareness: Pharmacoepidemiology and drug safety

  2010cites this paper
• 02 Characterising cardiovascular safety profile of muscarinic antagonist, ipratropium

  2010influential citation
• Cardiovascular Safety of Inhaled Anticholinergic Agents for COPD

  2010cites this paper
• Drugs that Act on the Respiratory Tract

  2010cites this paper
• Heart failure and chronic obstructive pulmonary disease : common partners, common problems.

  2010cites this paper
• Anticholinergic drugs for the treatment of COPD are safe... are they?

  2010cites this paper